Abstract
Objective To detect the expression of T helper cells 9 (Th9) in the peripheral blood,interleukin (IL)-9 level in the serum and the IL-9 in the tumor tissues of patients with laryngeal squamous cell carcinoma (LSCC),and analyze the relationship between Th9/IL-9 and clinical characteristics and their possible roles in the immunological pathogenesis of LSCC.Methods Sixty-six patients with LSCC and 40 healthy controls were included.Th9 cells in the peripheral blood were detected by flow cytometry.The serum IL-9 level was measured by enzyme-linked immunosorbent assay (ELISA).Immunohistochemistry (IHC) was used to determine the IL-9 expression in paraffin-embedded tissues of patients with LSCC.The relationship between Th9/IL-9 and clinical characteristics was analyzed.Results The level of Th9 cells in peripheral blood and IL-9 levels in serum of patients with LSCC were (2.64 ± 0.24) ％ and (89.40 ± 6.66) ng/L,respectively,significantly higher than those of healthy controls [(1.07 ± 0.11)％,t =12.63,P ＜0.01 ; (26.80 ±3.76) ng/L,t =14.37,P ＜0.01].Patients with Ⅲ-Ⅳ stage had higher Th9 cells and IL-9 levels than those with Ⅰ-Ⅱ stage [(3.21 ± 0.22) ％ vs.(2.07 ± 0.19) ％,t =8.24,P ＜0.01 ; (104.30 ±6.07) ng/L vs.(72.90 ±5.37) ng/L,t =8.91,P ＜0.01].Compared with peritumor tissues,intratumor tissues showed higher expression of IL-9 + cells (84.37％ vs.21.87％,x2 =25.098,P ＜ 0.01).The levels of Th9 cells in peripheral blood and IL-9 in serum were associated with tumor stage,tumor differentiation and regional lymph node metastasis (P ＜ 0.05),while the IL-9 + cells in tumor tissues were associated with tumor stage and regional lymph node metastasis (P ＜ 0.05).Conclusion There are higher quantification of Th9 cells and IL-9 in the peripheral blood and intratumor tissues in patients with LSCC,and they have positive correlation with the clinical stage.Th9 cells and IL-9 may contribute to the disease progression and prognosis of LSCC. Key words: T helper cells 9; Interleukin-9; Laryngeal squamous cell carcinoma
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
